Founded in 2005, Biodesix discovers and commercializes cancer tests (diagnostics) that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile. Biodesix is advancing precision medicine by helping oncologists provide the right patient with the right treatment at the right time.
Biodesix – cancer diagnostics
Unlike most cancer diagnostics, Biodesix’ tests require only a blood draw (instead of a biopsy, where a sample of the tumor is removed from a patient’s body) and results are available within 72 hours. Biodesix’ team of scientists in Research and Development utilize an array of technologies to develop clinically validated proteomics and genomics blood- based assays. The combination of reproducible high-throughput protein expression measurements with proprietary advanced machine learning algorithms allows Biodesix to take advantage of the correlations between protein expression and clinically relevant data to build molecular tests which can be validated and commercialized using the same development platform. VeriStrat, its serum proteomic test, is one example of Biodesix’ capabilities to discover and develop a robust diagnostic test with clinical utility. Biodesix’ goal is to help its partners rapidly pilot, develop and commercialize clinically relevant tests, including companion diagnostics. Biodesix’ research and development activities are conducted with the highest clinical integrity, including external validation with medical experts and properly designed and controlled clinical trials. Its internal controls are designed to ensure compliance with applicable federal, state, and local statutes and regulations relevant to providers of healthcare services.
Biodesix collaborates with leading researchers and builds strategic partnerships with biotechnology and pharmaceutical companies to develop companion diagnostics and build its pipeline of new products.
More about this biotech company : www.biodesix.com